Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis

Author:

Miloslavsky Eli M,Naden Ray P,Bijlsma Johannes W J,Brogan Paul A,Brown E Sherwood,Brunetta Paul,Buttgereit Frank,Choi Hyon K,DiCaire Jean-Francois,Gelfand Jeffrey M,Heaney Liam G,Lightstone Liz,Lu Na,Murrell Dedee F,Petri Michelle,Rosenbaum James T,Saag Kenneth S,Urowitz Murray B,Winthrop Kevin L,Stone John H

Abstract

ObjectivesTo develop a Glucocorticoid Toxicity Index (GTI) to assess glucocorticoid (GC)-related morbidity and GC-sparing ability of other therapies.MethodsNineteen experts on GC use and outcome measures from 11 subspecialties participated. Ten experts were from the USA; nine from Canada, Europe or Australia. Group consensus methods and multicriteria decision analysis (MCDA) were used. A Composite GTI and Specific List comprise the overall GTI. The Composite GTI reflects toxicity likely to change during a clinical trial. The Composite GTI toxicities occur commonly, vary with GC exposure, and are weighted and scored. Relative weights for items in the Composite GTI were derived by group consensus and MCDA. The Specific List is designed to capture GC toxicity not included in the Composite GTI. The Composite GTI was evaluated by application to paper cases by the investigators and an external group of 17 subspecialists.ResultsThirty-one toxicity items were included in the Composite GTI and 23 in the Specific List. Composite GTI evaluation showed high inter-rater agreement (investigators κ 0.88, external raters κ 0.90). To assess the degree to which the Composite GTI corresponds to expert clinical judgement, participants ranked 15 cases by clinical judgement in order of highest to lowest GC toxicity. Expert rankings were then compared with case ranking by the Composite GTI, yielding excellent agreement (investigators weighted κ 0.87, external raters weighted κ 0.77).ConclusionsWe describe the development and initial evaluation of a comprehensive instrument for the assessment of GC toxicity.

Funder

Genentech

Publisher

BMJ

Subject

General Biochemistry, Genetics and Molecular Biology,Immunology,Immunology and Allergy,Rheumatology

Reference18 articles.

1. The epidemiology of glucocorticoid-associated adverse events;Mcdonough;Curr Opin Rheumatol,2008

2. Incidence and US costs of corticosteroid-associated adverse events: a systematic literature review;Sarnes;Clin Ther,2011

3. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data;Da Silva;Ann Rheum Dis,2006

4. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma;Bel;N Engl J Med,2014

5. Tocilizumab induces corticosteroid sparing in rheumatoid arthritis patients in clinical practice;Fortunet,2015

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3